Teva's lupus drug flunks Phase II

Teva says its Phase II trial for the experimental lupus drug edratide failed to hit its primary endpoint. The weekly therapy failed to cut the rate of disease activity after 26 weeks of treatments. Teva says it will make a final determination on how to proceed after it crunches the numbers for secondary endpoints. The drug appeared safe and was well tolerated.

- check out the release for more info

Suggested Articles

Shorla Pharma picked up $8.3 million to push its cancer programs through U.S. regulatory approval and gear up for its first drug launch in 2021.

Nodthera bagged $55 million to get its lead asset through phase 1 and into proof-of-concept studies, and a second program into the clinic.

Genor Biopharma banked $160 million from the likes of Hillhouse and Temasek Holdings to advance its clinical-stage autoimmune and cancer programs.